pharma · Metastatic Breast Cancer · Talaromycosis
Duke University
Duke University is a pharma organization headquartered in CN. Primary therapeutic focus areas include Metastatic Breast Cancer, Talaromycosis. NovaPharmaNews links 2 clinical program(s), 0 drug profile(s), and 0 patent r
CN HQ
NMPA registrant Type
Company details
- Status
- Public
- HQ
- CN
- Programs
- 2
- Drugs
- 5
- Patents
- 0
Liposomal Amphotericin B (LAmB)
Phase 3 · small molecule · Talaromycosis
Liposomal Amphotericin B (LAmB) for Talaromycosis is a Phase 3 program (small_molecule) at Duke University with 1 ClinicalTrials.gov record(s).
Internal code Pro00113856
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Duke University
- Phase
- Phase 3
- Modality
- small_molecule
- Indication
- Talaromycosis
- Status
- active
- Trials
- 1